AREV Life Sciences Global Corp.
AREVF · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.27 | 0.04 | -0.08 |
| FCF Yield | -3.92% | -3.16% | -0.32% | -0.20% |
| EV / EBITDA | -20.22 | -35.82 | -51.44 | 32.03 |
| Quality | ||||
| ROIC | 1.18% | 12.09% | 17.44% | -11.16% |
| Gross Margin | 0.00% | 0.00% | 0.00% | -299.88% |
| Cash Conversion Ratio | 0.19 | 0.96 | 0.15 | -0.07 |
| Growth | ||||
| Revenue 3-Year CAGR | -64.86% | -45.63% | -41.20% | -36.36% |
| Free Cash Flow Growth | 95.18% | -363.27% | -256.99% | -38.11% |
| Safety | ||||
| Net Debt / EBITDA | -10.16 | -1.30 | -0.14 | 0.26 |
| Interest Coverage | -12.67 | -126.63 | -176.82 | 89.20 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -5,151.48 | -5,024.79 | -5,383.24 | -1,905.95 |